Could a new dissolving tablet quiet coughs? safety trial begins

NCT ID NCT07754279

Completed Knowledge-focused Sponsor: Materia Medica Holding Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether an experimental drug called MMH-522 is safe and tolerable for healthy people. About 16 volunteers aged 18 to 45 will take the tablet daily for 7 days, and researchers will monitor them for any side effects. The goal is to gather initial safety information to support future studies of the drug, which may eventually be developed as a treatment for cough.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MMH-522 (an experimental drug taken as a tablet that dissolves in the mouth)
What this could lead to: If MMH-522 proves safe, it could pave the way for larger studies to see if it helps with cough or other conditions.
What could go wrong: This is an early, small study in healthy people, so it won't show if the drug works for cough. Side effects are possible, and the drug may not be effective in future trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COUGH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COUGH

Contacts and locations

Locations

First Moscow State Medical University named after I.M. Sechenov/Center for Clinical Research of Drugs

Moscow, 119991, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.